ClinicalTrials.gg
CompletedNCT02629328CTRSUpdated Jan 29, 2019

CardioCel Tri-leaflet Repair Study

An interventional study of CardioCel in Aortic Stenosis and Aortic Insufficiency, sponsored by Anteris Technologies Ltd.. Completed at 1 site in Belgium. Open to participants aged Up to 85 Years. Per ClinicalTrials.gov, last updated 2019-01-29.

Sponsored by Anteris Technologies Ltd. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
Up to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Aortic Valve Stenosis with a site in Belgium — 11 open to participants now, 14 under way, 1 of them phase 3. Aortic Valve Stenosis · Belgium.

Enrollment
26th of 27
28 · median 214
Started
2015
with 3 others
No phase
22 of 47
5 open now
Registered
17th of 47
by date
Lead sponsor
2 of 47
Anteris Technologies Ltd.

Among the 47 studies in Aortic Valve Stenosis with a site in Belgium, this one is the 26th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2015, is one of 22 with no phase, and was the 17th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

11 of the 47 studies in Aortic Valve Stenosis with a site in Belgium are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: Up to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Aortic Valve Stenosis with a site in Belgium, or all of them as a file.
02

Study summary

This study will quantify the safety and efficacy of the CardioCel implant in tri-leaflet repair. 80 patients in up to 7 sites in Europe and the US will all be treated with the CardioCel implant.

Read the detailed description

The purpose of this study is to evaluate the safety and efficacy of the CardioCel for the repair of aortic valve stenosis and/or insufficiency. CardioCel is a cardiovascular patch manufactured with the so called ADAPT® technology. The ADAPT technology uses bovine spongiform encephalopathy-free pericardium which is processed in several ways to make it biocompatible with human tissue. CardioCel should provide an off the shelf material solution for tri-leaflet repair surgery due to its functional attributes, low propensity for post implant calcification, and overall biocompatibility. As a result adverse events and complications associated with the autologous pericardium repair surgery are mitigated.

In this study patients suffering from moderate-to-severe aortic stenosis and/or aortic insufficiency will be included.

In this study 80 patients will be enrolled in up to 7 centers in Europe and the US. The expected study duration is 36 months; 12 months of recruitment and 24 months follow-up.

CardioCel is US FDA cleared for the repair of cardiac and vascular defects, including intra-cardiac defects; septal defects, valve and annulus repair, great vessel reconstruction, peripheral vascular reconstruction, suture line buttressing and pericardial closure.

03

Conditions studied

  • Aortic Stenosis
  • Aortic Insufficiency

Keywords

  • CardioCel
  • FDA cleared
  • Tri-leaflet repair
  • Aortic valves
04

Who can participate

Ages eligible
Up to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject's annular measurements are ≥ 19 mm to \< 27mm as confirmed on pre-op echo and inter commissure distance equal to or bigger than 19mm as confirmed intraoperatively.
  2. The subject is suitable for a tri-leaflet repair.
  3. The subject has documented moderate-to-severe AS and/or AI.
  4. The subject is willing and able to comply with specified follow-up evaluations, including trans oesophageal echocardiography (TEE) if there are inadequate images by transthoracic echocardiography (TTE) to assess the aortic valve. The subject has reviewed and signed the written form.
  5. The subject upon final intraoperative assessment has intracardiac anatomy suitable for tri-leaflet repair using CardioCel.

Exclusion criteria

Exclusion Criteria:

  1. Greater than 85 years of age at the time of consent.
  2. The subject's annular measurements \< 19 mm or > 27mm.
  3. All patients will be excluded who require emergent surgery (within 24 hours of a presentation to an emergency department) for any reason.
  4. The subject will be excluded with pre-existing valve prosthesis in the aortic position.
  5. Patients requiring repair of other cardiac valves will be excluded.
  6. The subject has active endocarditis.
  7. Heavily calcified aortic roots or "porcelain aortas" (as evidenced on cardiac echo).
  8. Leukopenia with a WBC of less than 3000 cells per microliter.
  9. Acute anaemia with a less than 8 g/dL.
  10. count less than 150.000 platelets/microliter.
  11. History of a defined bleeding diathesis or coagulopathy or the subject refuses blood transfusions.
  12. Active infection requiring antibiotic therapy (if temporary illness, subjects may enrol 2-4 weeks after discontinuation of antibiotics).
  13. Subjects in whom trans oesophageal echocardiography (TEE) is .
  14. Low (EF) \< 35%.
  15. \< 1 year, or severe comorbidities, such as cancer, dialysis, or severe at the investigator's discretion
  16. The subject is an illicit drug user, alcohol abuser, prisoner, institutionalised, or is unable to give .
  17. The subject is pregnant or lactating (non-pregnancy to be confirmed by pregnancy test for all child bearing potential females prior to enrolment).
  18. Recent (within 6 months) cerebrovascular accident (CVA) or a (TIA).
  19. Myocardial Infarction (MI) within one month of trial inclusion
  20. Upon intraoperative assessment of the intracardiac anatomy the patient is not suitable for tri-leaflet repair using CardioCel.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Other
    CardioCel

    Treatment with CardioCel implant

    Device: CardioCel

Interventions

  • DeviceCardioCel

    Treatment with CardioCel implant

06

What researchers measure

Primary outcomes

  1. In-hospital survival (defined as percentage of patients alive and discharged from the index operation - presented as the inverse, or standard surgical operative mortality)

    Time frame: Pre-operative to 14 days post-operative

  2. Changes in mean aortic valve gradients from preoperative (baseline screening) to 6 months post-valve repair assessed by transthoracic or transesophageal echocardiography

    Time frame: Pre-operative to 6 months post-valve repair

  3. Mean transaortic valve gradient, measured using echocardiography, postoperatively, and at 6 and 12 months after valve repair.

    Time frame: Up to 12 months post-valve repair

  4. Aortic regurgitation grade (assessed on a 0-4 scale), measured using echocardiography, postoperatively, and at 6 and 12 months after valve repair.

    Time frame: Up to 12 months post-valve repair

Secondary outcomes

  1. Changes from preoperative to 6-months postoperative in linear left ventricular (LV) diastolic and systolic dimensions measured from parasternal long axis views by echocardiography.

    Time frame: Pre-operative to 6 months post-valve repair

  2. Changes from preoperative to 6-months postoperative in left ventricular volume measured by the Simpson's Biplane method using echocardiography.

    Time frame: Pre-operative to 6 months post-valve repair

  3. Changes from preoperative to 6-months postoperative in LV mass (if calculated), using the area-length method, assessed by echocardiography.

    Time frame: Pre-operative to 6 months post-valve repair

  4. Changes in symptomatic status (NYHA CHF Classification) from preoperative to 6 months after aortic valve repair.

    Time frame: Pre-operative to 6 months post-valve repair

  5. Changes in patient reported outcomes (EQ-5D) from baseline to 26 week postoperative

    Time frame: Baseline to 26 weeks post-valve repair

  6. Implant procedure success (evaluated through post-procedure hospital discharge) measured by the incidence of pre-defined adverse events:

    Time frame: From study enrolment to 24 months post-valve repair

07

Study locations

1 site
  • Universtiy Hospital Leuven
    Leuven, 3000, Belgium
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of Jul 2017 and a completion of Nov 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2015
First posted
Dec 14, 2015
Start
Sep 2015
Primary completionActual
Jul 5, 2017
CompletionActual
Nov 19, 2018
Last update
Jan 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02629328
Lead sponsor
Anteris Technologies Ltd.
Responsible party
Sponsor
First posted
Dec 14, 2015
Start date
Sep 2015
Primary completion
Jul 5, 2017
Completion
Nov 19, 2018
Last update
Jan 29, 2019

Study contacts

Dominico Mazzitelli, M.D.
principal investigator · German Heart Centre of the Technical University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion